ATE369428T1 - Behandlung von gebärmutterhalskrebs - Google Patents

Behandlung von gebärmutterhalskrebs

Info

Publication number
ATE369428T1
ATE369428T1 AT99942661T AT99942661T ATE369428T1 AT E369428 T1 ATE369428 T1 AT E369428T1 AT 99942661 T AT99942661 T AT 99942661T AT 99942661 T AT99942661 T AT 99942661T AT E369428 T1 ATE369428 T1 AT E369428T1
Authority
AT
Austria
Prior art keywords
cervical cancer
nucleic acid
acid molecule
treatment
hpv
Prior art date
Application number
AT99942661T
Other languages
English (en)
Inventor
Diane Gajewczyk
Roy Persson
Fei-Long Yao
Shi-Xian Cao
Michel Klein
James Tartaglia
Phillipe Moingeon
Benjamin Rovinski
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of ATE369428T1 publication Critical patent/ATE369428T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A61B5/0263—Measuring blood flow using NMR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/026—Measuring blood flow
    • A61B5/029—Measuring blood output from the heart, e.g. minute volume
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle
    • Y10S977/803—Containing biological material in its interior
    • Y10S977/804—Containing nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT99942661T 1998-09-04 1999-09-03 Behandlung von gebärmutterhalskrebs ATE369428T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9929198P 1998-09-04 1998-09-04

Publications (1)

Publication Number Publication Date
ATE369428T1 true ATE369428T1 (de) 2007-08-15

Family

ID=22274255

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99942661T ATE369428T1 (de) 1998-09-04 1999-09-03 Behandlung von gebärmutterhalskrebs

Country Status (14)

Country Link
US (1) US6235523B1 (de)
EP (2) EP1108035B1 (de)
JP (2) JP2002524078A (de)
AT (1) ATE369428T1 (de)
AU (1) AU766403C (de)
CA (1) CA2342289C (de)
CY (1) CY1107762T1 (de)
DE (1) DE69936784T2 (de)
DK (1) DK1108035T3 (de)
ES (1) ES2291039T3 (de)
NZ (1) NZ510488A (de)
PT (1) PT1108035E (de)
SI (1) SI1108035T1 (de)
WO (1) WO2000014244A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002541822A (ja) 1999-04-14 2002-12-10 エム ユー エス シー ファンデーション フォー リサーチ ディベロップメント 組織特異的および病原体特異的毒性物質ならびにリボザイム
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
EP1228237A1 (de) * 1999-11-01 2002-08-07 Chiron Corporation Expressionsvektoren, transfektionssysteme, und verfahren zur verwendung
NZ523683A (en) * 2000-07-21 2004-08-27 Glaxo Group Ltd Codon-optimized papilloma virus sequences
EP1363938B1 (de) * 2000-08-03 2013-12-11 Johns Hopkins University An endoplasmatischen reticulums chaperonprotein gebundenes antigen als molekulärimpfstoff
DE10055545A1 (de) * 2000-11-09 2002-07-25 Deutsches Krebsforsch Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
US6923958B2 (en) * 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
FR2839072A1 (fr) * 2002-04-24 2003-10-31 Neovacs Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
EP1515987A2 (de) * 2002-04-24 2005-03-23 Universite Libre De Bruxelles Mutiertes hpv-16 e7 polypeptid, pharmazeutische zusammensetzung davon und verfahren zur seiner herstellung
CA2491034A1 (en) 2002-06-26 2004-01-08 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
AU2003284239B2 (en) * 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
EP1644048B1 (de) 2003-05-05 2015-04-29 Johns Hopkins University Anti-krebs-dna-vakzine mit einer für plasmide kodierenden signalsequenz, mutiertes onkoprotein-antigen und hitzeschockprotein
JP4840774B2 (ja) 2004-09-10 2011-12-21 旭硝子株式会社 経口投与ワクチン
ATE476528T1 (de) 2004-12-08 2010-08-15 Gen Probe Inc Nukleinsäuredetektion aus verschiedenen typen des humanen papillomavirus
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
WO2006073970A2 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
WO2006081323A2 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
EP2551282A3 (de) 2005-03-23 2013-02-13 Genmab A/S Antikörper gegen CD38 zur Behandling von multiplem Myelom
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
US20110110979A1 (en) * 2008-04-16 2011-05-12 Universite De Lausanne Method and vaccine for optimizing the specific immune responses
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CA2799205A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
EP2580243B1 (de) 2010-06-09 2019-10-16 Genmab A/S Antikörper gegen menschliches cd38
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
CN105018525B (zh) * 2014-08-12 2017-06-13 广东拓谱康生物科技有限公司 携带人乳头瘤病毒16型突变型E7m91抗原基因的重组腺相关病毒载体及其构建方法与应用
JP6863907B2 (ja) * 2018-01-05 2021-04-21 日本電信電話株式会社 演算回路

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744133A (en) * 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein

Also Published As

Publication number Publication date
NZ510488A (en) 2003-07-25
SI1108035T1 (sl) 2007-12-31
JP2002524078A (ja) 2002-08-06
EP1108035A2 (de) 2001-06-20
EP1108035B1 (de) 2007-08-08
AU766403C (en) 2004-05-27
WO2000014244A2 (en) 2000-03-16
CA2342289C (en) 2012-07-24
CY1107762T1 (el) 2013-06-19
ES2291039T3 (es) 2008-02-16
JP4205572B2 (ja) 2009-01-07
DE69936784D1 (de) 2007-09-20
AU5611899A (en) 2000-03-27
JP2004121263A (ja) 2004-04-22
WO2000014244A3 (en) 2000-06-02
CA2342289A1 (en) 2000-03-16
DK1108035T3 (da) 2007-09-24
PT1108035E (pt) 2007-11-20
AU766403B2 (en) 2003-10-16
EP1728865A1 (de) 2006-12-06
US6235523B1 (en) 2001-05-22
DE69936784T2 (de) 2008-04-30

Similar Documents

Publication Publication Date Title
DE69936784D1 (de) Behandlung von gebärmutterhalskrebs
ATE267211T1 (de) Impfstoff gegen hpv
BR9814487A (pt) "vacina"
FI875082A0 (fi) Dna-sekvensser deriverade fraon genom av papillomavirus, deras anvaendning foer in vitro diagnostiska aendamaol; samt framstaellning av antigeniska kompositioner.
EP1246644A4 (de) Induzierung zellulärer immunantworten auf humanen papillomavirus unter verwendung von peptiden und nukleinsäure-zusammensetzungen
NO20013701L (no) HER-2/neu-fusjonsproteiner
AR039005A1 (es) Antigenos virales
ATE326479T1 (de) Varianten von antigenen des menschlichen papillomvirus
MY139500A (en) Optimized expression of hpv 58 l1 in yeast
DK1349926T3 (da) Komplementerende cellelinier
BR0316158A (pt) Vacina de vetor adenoviral
LU91397I2 (fr) "La protéine L1 recombinante du papillomavirus humain de type 6" Gardasil-Silgard
CA2042236A1 (en) Seroreactive epitopes on proteins of human papillomavirus (hpv) 18
KR970705408A (ko) 헤모필루스 부착 및 침투 단백질(haemophilus adherence and penetration proteins)
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
AR041515A1 (es) Vacuna a dna contra el virus de papiloma humano
NZ516725A (en) Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
WO1997004099A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
ATE366583T1 (de) Identifizierung von spezifischen differenziell exprimierten antigenen aus mycobacterium und medizinische verwendung der mycobakteriumproteine rv0068 und rv3407
WO1998023752A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
WO1999009177A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
WO1998042847A3 (de) Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung
ES2171657T3 (es) Vector de dna recombinante para terapia genica.
WO2000014112A3 (de) Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen
ES2105984A1 (es) Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas.